Merck is cutting production and staff at their Riverside, Pa. manufacturing plant. The company plans to outsource some work and sell the plant's fermentation operations, according to Fierce Pharma.
Merck isn't shutting down the facility altogether. Instead, the company will focus its operations there on two antibiotics, Invanz and Primaxin, while bringing in a buyer to operate the fermentation line. The company will outsource production of APIs for a cholesterol drug and an AIDS treatment.
Some jobs will have to go, but Merck officials say they don't know how many. They also don't know when, spokeswoman Betse Humphrey said, because it will take time to outsource some of the production and to sell the fermentation operations. "The important thing is we are focusing on our antibiotic franchise," Humphrey said. "It's good news. We're looking at this as a way to remain in the community."